India's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based ...
A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...
Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path ...
Healthcare Asia Magazine on MSN
CNS drug market to hit $235.9b by 2033 as neurological diseases surge
Mergers and licensing deals are accelerating as the global market valuation nears quarter-trillion mark. The global market ...
The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...
Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...
Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare ...
After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...
NEW YORK – The European Commission has approved a high-dose regimen of Biogen's Spinraza (nusinersen), an antisense oligonucleotide for 5q spinal muscular atrophy (SMA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback